Background {#Sec1}
==========

Randomised controlled trials (RCTs) are considered one of the simplest and most powerful tools for assessing the safety and effectiveness of treatment interventions \[[@CR1]--[@CR3]\]. When appropriately designed, conducted and reported, RCTs can produce an immediate impact on clinical practice and patient care \[[@CR4]\].

The evolution of RCTs has been an enduring and continuing process \[[@CR5]--[@CR15]\]. Since the 1970s the publication landscape for RCTs has exhibited an exponential growth. For example, a 1965--2001 bibliometric analysis of the literature identified 369 articles published in 1970 compared to 11,159 published in 2000 \[[@CR5]\]. The development of clinical trial registries (such as clinicaltrials.gov) \[[@CR9], [@CR10]\], the exponential increase in journals publishing trial protocols, results and secondary studies, and growing support for data-sharing policies \[[@CR11], [@CR12]\] have created an open research environment of transparency and accountability. Furthermore, the publication of reporting guidelines (such as CONSORT and SPIRIT) \[[@CR4], [@CR13]--[@CR15]\] have served to facilitate the transition between research and reporting to ensure standardisation and ease of readability.

RCTs published in major medical journals are highly cited and have an instrumental role in clinical practice and health policy decisions \[[@CR5], [@CR16], [@CR17]\]. Previous studies have focused on the quality of the reporting of methods and results of RCTs \[[@CR18]--[@CR22]\] and publication practices \[[@CR23]--[@CR28]\] in selected samples of articles published in high-impact-factor (IF) medical journals. However, to the best of our knowledge, no mapping studies have been conducted on major medical journals to investigate the most common subjects, most productive scientists and countries, most prolific journals and "citation classics" across multiple specialties.

The objective of this study was to describe and characterise the global clinical research publication activity through RCT articles published in high-IF medical journals during the past decades.

Methods {#Sec2}
=======

Eligibility criteria {#Sec3}
--------------------

This cross-sectional analysis investigated RCT-related articles (that is, primary RCTs, secondary analyses and methodology papers using clinical data) published in major medical journals. We excluded narrative reviews, systematic reviews, meta-analyses, pool-analyses, letters and newspaper articles. All RCT-related articles indexed in PubMed/MEDLINE had to be published in one of the major medical journals with an IF exceeding 10 (2016 IF according to the Journal Citation Reports \[JCR\] published in June 2017). These medical journals were chosen because they were identified as publishing clinical research with scientific merit and clinical relevance (see Table [1](#Tab1){ref-type="table"} for a list of the included medical journals). Table 1Included high-impact-factor medical journalsGeneral medicine journals (with an IF \> 10):- *The New England Journal of Medicine* (IF = 72.406)- *The Lancet* (IF = 47.831)- *JAMA* -- *the Journal of the American Medical Association* (IF = 44.405)- *The BMJ* -- *the British Medical Journal* (IF = 20.785)- *Annals of Internal Medicine* (IF = 17.202)- *JAMA Internal Medicine* -- formerly, Archives of Internal Medicine (IF = 16.538)- *PLOS Medicine* (IF = 11.862)Medical specialty journals (with an IF \> 10):- *Lancet Oncology* (IF = 33.900)- *World Psychiatry* (IF = 26.561)- *Lancet Neurology* (IF = 26.284)- *Journal of Clinical Oncology* (IF = 24.008)- *European Heart Journal* (IF = 20.212)- *JACC* -- *Journal of the American College of Cardiology* (IF = 19.896)- *Lancet Infectious Diseases* (IF = 19.864)- *Lancet Diabetes & Endocrinology* (IF = 19.742)- *Circulation* (IF = 19.309)- *Lancet Respiratory Medicine* (IF = 19.287)- *Gastroenterology* (IF = 18.392)- *Gut* (IF = 16.658)- *JAMA Oncology* (IF = 16.559)- *European Urology* (IF = 16.265)- *JAMA Psychiatry* -- formerly, Archives of General Psychiatry (IF = 15.307)- *American Journal of Psychiatry* (IF = 14.176)- *Circulation Research* (IF = 13.965)- *Hepatology* (IF = 13.246)- *American Journal of Respiratory and Critical Care Medicine* (IF = 13.204)- *Blood* (IF = 13.164)- *Journal of Allergy and Clinical Immunology* (IF = 13.081)- *Annals of the Rheumatic Diseases* (IF = 12.811)- JNCI -- *Journal of the National Cancer Institute* (IF = 12.589)- *Journal of Hepatology* (IF = 12.486)- *Intensive Care Medicine* (IF = 12.015)- *Diabetes Care* (IF = 11.857)- *Annals of Oncology* (IF = 11.855)- *Leukaemia* (IF = 11.702)- *Lancet Psychiatry* (IF = 11.588)- *European Respiratory Journal* (IF = 10.569)- *Brain* (IF = 10.292)- *JAMA Pediatrics* -- formerly, Archives of Pediatrics & Adolescent Medicine (IF = 10.251)- *JAMA Neurology* -- formerly, Archives of Neurology (IF = 10.029)

Search {#Sec4}
------

On March 22, 2018, we systematically searched MEDLINE through PubMed (National Library of Medicine, Bethesda, MD, United States) for all RCT-related articles published in high-IF medical journals (from inception to December 31, 2017). A senior information specialist (AA-A) and a clinical epidemiologist (FC-L) designed an electronic literature search using a validated research methodology filter for RCTs (with 97% specificity and 93% sensitivity) \[[@CR29]\]. The search was peer reviewed by members of the study team, including a second (senior) information specialist (RA-B). The full search strategy is provided in Additional file [1](#MOESM1){ref-type="media"}. On May 7, 2018, we searched the Web of Science (WoS) (Clarivate Analytics, Philadelphia, Penn., United States) by using PubMed IDs (PMIDs) from the PubMed/MEDLINE searches. Merging MEDLINE with other citation indices such as the WoS combines the advantages of MEDLINE (e.g., Medical Subject Headings \[MeSH\], a comprehensive controlled vocabulary for indexing journal articles) with the relational capabilities and data of the WoS \[[@CR30]\].

Data extraction and normalisation {#Sec5}
---------------------------------

For each included article, raw (meta) data on the journal and article titles, subject category, the year of publication, keywords, and the authors' names, institutional affiliation(s), funding source, and country was downloaded online through the WoS by one researcher (A-AA). We also used the WoS to determine the extent to which each article had been cited in the scientific peer-review literature using the "times cited" number (that is, the number of times a publication has been cited by other publications). Two researchers (FC-L, RA-B) independently verified the data to minimise potential information errors. A process of normalisation was conducted by two researchers to bring together the different names of an author or country and the keywords (further details are available in Additional file [2](#MOESM2){ref-type="media"}). Specifically, one researcher (AA-A) checked the names by which an individual author appeared in two or more different forms (for example, "John McMurray" or "John J. McMurray" or "John J.V. McMurray") using coincidence in that author's place(s) of work as the basic criterion for normalisation (for example, University of Glasgow, Scotland, United Kingdom) \[[@CR31]\], and a second researcher (FC-L or RA-B) verified the data. A threshold of 30 articles was applied to review 200 names by which an individual author appeared in two or more different forms.

We extracted both "author keywords" and "keyword plus," which are automatically assigned by the WoS from the titles of the references of the articles, as topical (also called textural, linguistic or sematic) data \[[@CR32]\]. To ensure consistency in the data, one researcher (RA-B) corrected keywords by unifying grammatical variants and using only one keyword developed to name the same concept (for example, "randomized trial" or "randomized clinical trial" or "randomized controlled trial" or "randomised controlled trial"). In addition, the same researcher (RA-B) removed typographical, transcription and/or indexing errors, and a second researcher (FC-L) verified the data. All potential discrepancies were resolved via consensus amongst these investigators. All these data were collected and entered into a Microsoft Access® (Microsoft, Seattle, WA, United States) database between May 7, 2018, and January 9, 2019.

Data analysis {#Sec6}
-------------

We analysed data for the number of articles, citations, signatures (or total number of authors included in all the articles of each author), collaboration index (that is the mean number of author's signatures per article), countries, journals and keywords. Data were summarised as frequencies and percentages for the categorical items. The most prolific authors (\>100 articles), countries (\>100 articles), funding institutions (\>100 articles), and the most cited papers ("top-100 citation classics") were identified. Network plots were generated for intense scientific collaboration between countries (applying a threshold of 100 articles in collaboration).

We conducted an exploratory analyses of topical data using a set of unique keywords and their frequencies to examine the topic coverage, major topics ("word clouds" of keywords) and their interrelations ("co-words networks") in RCT articles. The main goal in topical analyses is to understand the topical distribution of a dataset, i.e. what topics are covered and how much of each topic is covered in a scientific discipline \[[@CR32]\]. The most frequently used keywords were identified for the most prolific journals (with at least 1000 articles). Based on the most frequently used keywords (with at least 500 articles), a word cloud was created from text that the user provides and more emphasis was placed on words that appear with greater frequency in the source text. A "co-words network" was created to illustrate the co-occurrence of highly frequent words in the articles (applying a threshold of 100 articles in collaboration). The network analysis was carried out with the use of PAJEK (University of Ljubljana, Slovenia) \[[@CR33]\], a software package for large network analysis that is free for non-commercial use to construct network graphs. The PRISMA checklist \[[@CR34]\] (<http://www.prisma-statement.org/>) guided the reporting of the present analysis (and is available in Additional file [3](#MOESM3){ref-type="media"}).

Results {#Sec7}
=======

A total of 39,329 records were identified by the PubMed/MEDLINE search (Fig. [1](#Fig1){ref-type="fig"}), and 39,305 articles met the study inclusion criteria (Additional file [4](#MOESM4){ref-type="media"}) after 24 records had been excluded (Additional file [5](#MOESM5){ref-type="media"}). Table [2](#Tab2){ref-type="table"} details the general characteristics of the articles. Fig. 1Flow diagram with selection of articles Table 2General characteristics of the study sampleCharacteristicNumberPercentTotal number of articles39,305100.0Journal (top-10) The Lancet35939.1 Journal of Clinical Oncology33438.5 The New England Journal of Medicine32758.3 The BMJ25166.4 Circulation23315.9 JACC Journal of the American College of Cardiology21335.4 JAMA19044.8 Diabetes Care18854.8 Journal of Allergy and Clinical Immunology13453.4 European Heart Journal13153.3Year of publication Before 198020045.1 1980--1989404010.3 1990--1999962624.5 2000--200912,57432.0 2010--201711,06128.1Journal impact factor (2016) 10.0--15.012,15030.9 15.1--20.010,38826.4 20.1--25.0717418.3 25.1--30.02380.6  \>30.0935523.8Main subject category^a^ Medicine, General & Internal13,68830.7 Cardiac & Cardiovascular Systems582813.1 Oncology576012.9 Gastroenterology & Hepatology30236.8 Psychiatry23805.3Number of citations 0--5015,44939.3 51--100871422.2 101--50013,05633.2 501--100014453.7  \>10006411.6Number of authors 110642.7 2--334058.7 4--610,34026.3 7--1011,14228.3  \>1013,35434.0Country of first author (top-10) United States14,50836.9 United Kingdom492412.5 The Netherlands18744.8 Germany18624.7 Canada18474.7 France17324.4 Italy17204.4 Australia9992.5 Sweden7551.9 Denmark6601.7Source of funding Reported16,48541.9 None/not reported22,82058.1^a^Subject category according to Journal Citation Reports (JCR)

Publication trend {#Sec8}
-----------------

The number of articles increased exponentially over the period 1965--2017 (Fig. [2](#Fig2){ref-type="fig"}). Approximately 60% (*n* = 23,635) of the articles have been published since 2000. Fig. 2Number of articles by year of publication

Journals and subject category {#Sec9}
-----------------------------

Forty journals published 39,305 articles, and 23.8% of them (*n* = 9355) were published by four journals with an IF \> 30. *The Lancet* (9.1%; *n* = 3593), the *Journal of Clinical Oncology* (8.5%; *n* = 3343) and *The New England Journal of Medicine* (8.3%; *n* = 3275) published the largest number of articles, followed by *The BMJ* (6.4%; *n* = 2516) and *Circulation* (5.9%; *n* = 2331). Most articles were classified as "medicine, general & internal" (30.7%; *n* = 13,688); "cardiac & cardiovascular systems" (13.1%; *n* = 5828); or "oncology" (12.9%; *n* = 5760) according to the WoS journal categorisations (Table [2](#Tab2){ref-type="table"}).

Authors, institutions and countries {#Sec10}
-----------------------------------

Most articles (62.3%; *n* = 24,496) were written by seven or more authors, and only 11.4% (*n* = 4469) of the articles were written by three or fewer authors. The first authors of the articles were based most commonly in North America and Western Europe; first authors from the United States were responsible for 36.9% (*n* = 14,508) of the articles (Table [2](#Tab2){ref-type="table"}). We identified 17 authors who published 100 or more articles (Table [3](#Tab3){ref-type="table"}). All of the most productive authors were male. The most prolific authors were Robert M. Califf, with 239 articles (from Duke University, United States); Eugene Braunwald, with 218 (from Harvard University, United States); Salim Yusuf, with 217 (from McMaster University, Canada); Eric J. Topol, with 212 (from Scripps Translational Science Institute, United States); Harvey D. White, with 186 (from University of Auckland, New Zealand); Lars Wallentin, with 144 (Uppsala University, Sweden); and Christopher B. Granger, with 140 (from Duke University, United States). Table 3Most productive authors and their institutionsAuthorAffiliation and countryArticlesCitationsCitations per articleArticles in collaborationTotal signaturesCollaboration index (signatures per article)Califf, Robert M.Duke Clinical Research Institute, Duke University, United States23956,742237.4239791933.1Braunwald, EugeneBrigham and Women's Hospital, Harvard University, United States21863,764292.5218829638.1Yusuf, SalimMcMaster University, Canada21779,270365.3216916342.4Topol, Eric J.Scripps Translational Science Institute, United States21248,523228.9212622929.4White, Harvey D.Auckland City Hospital, University of Auckland, New Zealand18638,540207.2185913349.4Wallentin, LarsUppsala Clinical Research Centre, Uppsala University, Sweden14432,741227.4142295820.8Granger, Christopher B.Duke Clinical Research Institute, Duke University, United States14029,668211.9140502535.9Stone, Gregg W.New York-Presbyterian Hospital, Columbia University, United States13524,601182.2135192814.3Serruys, Patrick W.Imperial College London, United Kingdom andErasmus University, The Netherlands13327,302205.3133225316.9Armstrong, Paul W.University of Alberta Hospital, University of Alberta, Canada12525,992207.9124457336.9McMurray, John J.V.University of Glasgow, Scotland, United Kingdom11630,470262.7116342529.5Pfeffer, Marc A.Brigham and Women's Hospital, Harvard University, United States11646,032396.8115407035.4Gelber, Richard D.Dana-Farber Cancer Institute, Harvard University, United States10720,898195.3107331130.9Van de Werf, FransCatholic University of Leuven, University Hospital Leuven, Belgium10721,918204.8105449242.8Harrington, Robert A.Stanford University, United States10520,436194.6103497148.3Cannon, Christopher P.Brigham and Women's Hospital, Harvard University, United States10326,192254.3103224121.8Goldhirsch, AronEuropean Institute of Oncology, Italy10316,254157.898327933.5Note: Top authors with at least 100 articles

Overall, 154 countries worldwide contributed to the analysed articles. The publication productivity ranking for countries (Table [4](#Tab4){ref-type="table"}) was led by the United States (*n* = 18,393 articles, with 3.4 million citations), followed by the United Kingdom (*n* = 8028 articles, with 1.3 million citations), Canada (*n* = 4548 articles, with 1.0 million citations) and Germany (*n* = 4415 articles, with 0.9 million citations). A total of 37 countries had at least 100 articles in co-authorship. Figure [3](#Fig3){ref-type="fig"} shows a visual representation of the most intense collaborative network between these 37 countries, in which we can see the relationships of some countries with respect to others and the position that each occupies in the network. Table 4Productivity and patterns of collaboration by top countriesCountryTotal articlesArticles per million inhabitantsTotal collaborationsTotal citationsCitations per articleArticles in collaboration (distinct country)Distinct countries of collaborationMain collaborator (and number of collaborations)United States18,39356.525,3083,364,015182.97895130Canada (2892)United Kingdom8028121.618,5291,345,597167.64534128United States (2528)Canada4548123.913,0241,017,912223.83552108United States (2892)Germany441553.416,463894,026202.53416111United States (2034)France390058.115,093826,172211.82928119United States (1759)Italy360859.613,005674,367186.9243296United States (1446)The Netherlands3453201.510,578619,589179.4233199United States (1172)Australia235495.78787469,341199.41750103United States (1114)Belgium2197193.210,685482,974219.82016107United States (1068)Spain202043.49747417,291206.6158199United States (1017)Sweden1909189.67034376,159197.0148391United States (794)Switzerland1862219.97840348,734187.31621117United States (818)Denmark1523264.05572297,936195.6109084United States (582)Poland95325.16577222,301233.391680United States (650)Austria945107.34673192,799204.083285Germany (555)Japan8206.52232132,758161.937466United States (289)Finland797144.62950195,500245.355681United States (264)China7710.63292141,741183.855087United States (391)Norway756143.13076152,184201.360570Sweden (310)Israel66175.93364159,264240.954771United States (382)Brazil6263.04102154,296246.556798United States (440)New Zealand602125.62229106,318176.648080United States (293)Czech Republic48645.93757107,543221.347582United States (315)South Korea4749.2274880,338169.538378United States (322)South Africa4638.2246889,382193.042295United States (311)Russia4252.93449109,224257.042475United States (336)Greece41938.9211459,496142.028575United States (168)Hungary39240.1319293,590238.738374United States (249)Argentina3908.82736117,289300.735791United States (290)India3700.3201663,646172.0299101United States (214)Taiwan34114.5180377,089226.124263United States (194)Ireland29761.7136660,867204.926379United Kingdom (170)Mexico2532.0175456,256222.423084United States (195)Singapore19434.6121042,265217.917680United States (120)Turkey1892.3128834,928184.814979United States (92)Thailand1852.7126855,360299.217793United States (120)Portugal16816.3121824,177143.916061Belgium (89), France (89)Chile1578.7126537,556239.214981United States (112)Romania1497.6140631,392210.714877United States (110)Ukraine1132.5100729,880264.411361United States (84)Uganda1122.640514,931133.310872United States (78)Kenya1072.250818,737175.110383United States (68)Note: Top countries with at least 100 articles. Country inhabitants (year 2017) obtained from the World Bank (<http://data.worldbank.org/>) Fig. 3Global collaborative network between countries. Note: Most productive cluster of countries applying a threshold of 100 or more papers signed in co-authorship. Node sizes are proportional to the number of papers, and line thicknesses are proportional to the number of collaborations. Node colours: America = red; Asia = yellow; Africa = green; Europe = blue; Oceania = purple

Funding source {#Sec11}
--------------

A total of 16,485 articles (41.9%) reported sources of funding. The 40 most frequent funding institutions (with 100 or more articles) are listed in Table [5](#Tab5){ref-type="table"}. The main funders were the National Institutes of Health (NIH), with 7422 articles; Hoffmann-La Roche (*n* = 1188), Pfizer (*n* = 1139), Merck Sharp & Dohme (*n* = 1097) and Novartis (*n* = 1052). Table 5Most frequent funding institutionsFunding institution and countryFunding typeArticlesCitationsCitations per articleArticles in collaborationJournalsMain journals (number of articles)National Institutes of Health (NIH), United StatesNon-industry74221,312,297176.8218739Journal of Clinical Oncology (1096), The New England Journal of Medicine (869), JAMA (614)Hoffmann-La Roche, SwitzerlandIndustry1188218,428183.999736The New England Journal of Medicine (159), Journal of Clinical Oncology (155), Lancet Oncology (96)Pfizer, Inc., United StatesIndustry1139197,275173.2100136The New England Journal of Medicine (187), JACC (112), Journal of Clinical Oncology (82)Merck Sharp & Dohme (MSD), United StatesIndustry1097189,047172.397835The New England Journal of Medicine (156), JACC (145), Diabetes Care (116)Novartis, SwitzerlandIndustry1052192,229182.790034The New England Journal of Medicine (157), JACC (107), Journal of Clinical Oncology (81)Sanofi, FranceIndustry987170,078172.392034JACC (152), Diabetes Care (142), The New England Journal of Medicine (135)AstraZeneca, United KingdomIndustry938168,667179.884133JACC (166), The New England Journal of Medicine (131), Diabetes Care (101)GlaxoSmithKline, United KingdomIndustry937174,377186.183235The New England Journal of Medicine (154), JACC (95), Diabetes Care (88)Bristol-Myers Squibb (BMS), United StatesIndustry924186,731202.184333The New England Journal of Medicine (141), JACC (121), Diabetes Care (119)Johnson & Johnson, United StatesIndustry873153,063175.379134The New England Journal of Medicine (136), JACC (113), Diabetes Care (90)Abbott Laboratories, United StatesIndustry843141,475167.875833JACC (218), The New England Journal of Medicine (129), Diabetes Care (71)Eli Lilly and Company, United StatesIndustry796118,087148.472729Diabetes Care (144), JACC (133), The New England Journal of Medicine (88)Boehringer Ingelheim, GermanyIndustry600125,626209.453731The New England Journal of Medicine (115), Diabetes Care (89), JACC (78)Medtronic, United StatesIndustry56595,746169.552525JACC (186), The New England Journal of Medicine (84), Diabetes Care (65)National Institute of Health Research (NIHR), United KingdomNon-industry50242,35884.440940The Lancet (76), The BMJ (66), The New England Journal of Medicine (35)Amgen Inc., United StatesIndustry48883,923172.042425The New England Journal of Medicine (88), Journal of Clinical Oncology (65), JACC (64)Bayer AG, GermanyIndustry487107,327220.445333The New England Journal of Medicine (89), JACC (84), Circulation (42)Medical Research Council (MRC), United KingdomNon-industry42667,256157.930439The Lancet (84), The BMJ (47), The New England Journal of Medicine (29)Takeda Pharmaceutical Company, JapanIndustry39283,259212.435428Diabetes Care (71), The New England Journal of Medicine (70), JACC (44)National Health and Medical Research Council (NHMRC), AustraliaNon-industry33835,116103.927638Diabetes Care (34), The New England Journal of Medicine (34), The Lancet (34)Daiichi Sankyo Company, JapanIndustry33652,054154.932518JACC (105), Diabetes Care (46), The New England Journal of Medicine (43)Boston Scientific Corporation, United StatesIndustry31745,609143.929114JACC (140), Circulation (58), European Heart Journal (38)Novo Nordisk, DenmarkIndustry30644,994147.027326Diabetes Care (162), The New England Journal of Medicine (38), The Lancet (24)Gilead Sciences, United StatesIndustry30153,978179.324422The New England Journal of Medicine (67), JACC (49), Hepatology (26)Wellcome Trust, United KingdomNon-industry27632,785118.814236The Lancet (67), The BMJ (34), PLOS Medicine (26)Canadian Institutes of Health Research (CIHR), CanadaNon-industry26627,300102.621630The New England Journal of Medicine (46), JAMA (29), The Lancet (22)Cancer Research UK, United KingdomNon-industry22923,766103.820221Lancet Oncology (64), Journal of Clinical Oncology (45), Annals of Oncology (27)Allergan plc, IrelandIndustry20332,028157.819526American Journal of Psychiatry (39), The New England Journal of Medicine (27), JACC (18)Servier, FranceIndustry19933,106166.419420JACC (51), The New England Journal of Medicine (29), European Heart Journal (24)Astellas Pharma Inc., JapanIndustry19338,282198.417829The New England Journal of Medicine (38), European Urology (18), JACC (16)Teva Pharmaceutical Industries Ltd., IsraelIndustry17529,128166.416724The New England Journal of Medicine (29), Lancet Neurology (20), Journal of Allergy and Clinical Immunology (18)The Medicines Company, United StatesIndustry17526,314150.416510JACC (76), Circulation (29), The New England Journal of Medicine (28)Eisai Co., Ltd., JapanIndustry16136,321225.615022The New England Journal of Medicine (34), JACC (30), Circulation (16)Merck KGaA, GermanyIndustry15635,146225.313420The New England Journal of Medicine (24), Annals of Oncology (21), Lancet Oncology (20)Otsuka Pharmaceutical Co., Ltd., JapanIndustry13821,029152.413020JACC (31), American Journal of Psychiatry (31), The New England Journal of Medicine (14)Bill & Melinda Gates Foundation, United StatesNon-industry13515,839117.39515The Lancet (33), PLOS Medicine (27), The New England Journal of Medicine (24)Celgene Corporation, United StatesIndustry13426,369196.810219Journal of Clinical Oncology (31), The New England Journal of Medicine (26), Blood (20)Federal Ministry of Education and Research (BMBF), GermanyNon-industry11911,40995.910428Journal of Clinical Oncology (14), Blood (10), Diabetes Care (9)UCB, BelgiumIndustry11816,085136.310014Annals of the Rheumatic Diseases (47), Lancet Neurology (14), The New England Journal of Medicine (13)Biotronik, GermanyIndustry10415,554149.6967JACC (44), European Heart Journal (22), The New England Journal of Medicine (19)

Most cited articles {#Sec12}
-------------------
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Common keywords {#Sec13}
---------------

The most commonly used article keywords were "clinical trial" (16.1%; *n* = 6332 papers), followed by "therapy" (10.8%; *n* = 4267), "randomised controlled trial" (6.6%; *n* = 2587), "chemotherapy" (5.6%; *n* = 2224), "risk" (5.1%; *n* = 2026), "efficacy" (4.9%; *n* = 1933) and "double-blind" (4.9%; *n* = 1929). The most frequently used keywords in the most prolific journals are shown in Table [7](#Tab7){ref-type="table"}. In addition, exploratory analyses of word clouds and networks based on keywords (co-words) showed the broad range of the topics covered (see Additional file [6](#MOESM6){ref-type="media"}). Table 7Most prolific journals and most commonly used keywords per journalJournal subject categoryTotal articlesJournal nameTotal articlesKeywordsTotal articlesGeneral medical journals13,688*The Lancet*3593Clinical trial331Therapy310Efficacy175Management167Risk164*The New England Journal of Medicine*3275Clinical trial875Randomised controlled trial511Therapy385Double-blind238Risk201*The BMJ*2516Clinical trial151Management109Intervention96Therapy88Risk77*JAMA*1904Clinical trial237Therapy153Risk136Meta-analysis130Double-blind127*JAMA Internal Medicine*1122Clinical trial151Risk98Randomised controlled trial93Intervention84Cardiovascular disease81*Annals of Internal Medicine*1097Clinical trial140Therapy96Risk75Disease62Efficacy55Specialised medical journals25,617*Journal of Clinical Oncology*3343Chemotherapy1028Clinical trial772Therapy646Survival442Randomised controlled trial385*Circulation*2331Myocardial infarction690Clinical trial618Cardiovascular disease578Therapy466Coronary heart disease454*JAAC -- Journal of the American College of Cardiology*2133Myocardial infarction355Clinical trial345Cardiovascular disease281Mortality258Randomised controlled trial247*Diabetes Care*1885Diabetes mellitus779Glycaemic control305Clinical trial272Therapy225Risk189*Journal of Allergy and Clinical Immunology*1354Asthma446Children364Double-blind238Clinical trial232Histamine222*European Heart Journal*1315Clinical trial231Myocardial infarction228Mortality159Therapy159Cardiovascular disease153*Annals of Oncology*1119Chemotherapy448Clinical trial353Therapy236Survival169Carcinoma130*American Journal of Respiratory and Critical Care Medicine*1011Asthma316Clinical trial270Therapy182Chronic obstructive pulmonary disease178Bronchial hyperresponsiveness148*Gastroenterology*1008Clinical trial158Therapy122Randomised controlled trial86Inflammatory bowel disease75Cirrhosis63Note: Journals with at least 1000 articles. Keyword data refer to the period 1990--2017

Discussion {#Sec14}
==========

In this cross-sectional analysis, we presented a global mapping of RCT-related articles published in high-IF medical journals for the period 1965--2017. We identified the most prolific scientists, institutions and countries, main funding sources, most common subjects and topics, "citation classics" and most prolific high-IF medical journals from multiple specialties over the last 50 years.

In general, we found a strong clustering of articles published in British and American medical journals (*The Lancet, Journal of Clinical Oncology, The New England Journal of Medicine, The BMJ*, *Circulation, JAMA, JACC* and *Diabetes Care* accounted for 53% of the RCT-related articles). Many of these journals have been developed by active medical associations, both nationally and internationally. We hypothesize that different publishing patterns between journals may potentially reflect editorial policies and/or preferences, with some general medicine journals (such as *The Lancet and The New England Journal of Medicine*) and specialty journals (such as *Journal of Clinical Oncology* and *Circulation*), being more interested in and/or promoting the publication of RCTs. In contrast, a substantial number of these articles are behind publication paywalls (very few of the medical journals in our study sample are Open Access), and thus, research results may not be accessible to a large fraction of the scientific community and society as a whole, including clinicians (and patients) who may want them to help inform their clinical practice.

The results of this study highlight the expanding collaborative networks between countries in multiple regions, revealing a discernible scientific community, with the most productive countries having an important number of collaborations. Publication activity efforts were global during the study period, with articles from scientists and institutions in more than 150 different countries. However, the scientific community is centred on a nucleus of scientists from Western countries, with the most intense global collaborations taking place among the United States, United Kingdom and Canada. The presence and influence that these countries have on biomedical research \[[@CR64]--[@CR66]\] may be due to their large multi-stakeholder research partnerships, greater financial investment in clinical research, and high population of active scientists and research centres compared to other countries.

Publication activity worldwide shows that low- and middle-income countries have low levels of articles in high-IF medical journals. Difficulties in healthcare, education and research systems, information access and communication, language barriers and economic and institutional instability all represent challenges (and clear disadvantages) for productivity in low- and middle-income regions. In addition, restrictions and difficulties in conducting clinical research in resource-poor situations result in the exclusion of many of these countries from the planning, conduct and publication of RCTs \[[@CR67]--[@CR69]\]. As might be expected, our results support previous findings that low- and middle-income countries \[[@CR31], [@CR70], [@CR71]\] had minimal contributions in articles published in major medical journals. For example, a previous study \[[@CR70]\] showed that most of the authors of original papers published in five high-impact general medical journals (including *The New England Journal of Medicine*, *The Lancet*, *JAMA, The BMJ* and *Annals of Internal Medicine*) were more frequently affiliated with institutions in the same country as the journal. To address some of these problems, scientists, institutions and funders should promote collaborations (beyond historical, cultural and political factors) to share knowledge, expertise and innovative methodologies for clinical research. This may involve partnerships with Western countries to support capacity and resource development and research training.

RCT-related articles were published most often in high IF medical journals devoted to general and internal medicine, cardiology and oncology (nearly 57% of all articles). Similarly, the lists of the most cited articles identified topics which reflect major advances in the management of chronic conditions (such diabetes, cardiovascular disorders and cancer). The large relative productivity in general internal medicine, cardiology and oncology may be explained by the important role of randomised evidence to novel treatments and preventive strategies for these chronic diseases. In line with previous research \[[@CR72]--[@CR75]\], most of these highly cited RCTs addressed interventions for burdensome conditions that are health priorities in Western countries \[[@CR76], [@CR77]\]. Funding of (international, collaborative) RCTs may come from varying sources including commercial and non-commercial sponsors. However, previous analyses of RCT-related articles published in high-IF journals have suggested that study sponsors may influence how RCTs are designed, conducted and reported, sometimes serving financial rather than public interests \[[@CR78]\]. Given that research funding is often restricted, the scientific community is responsible for using the available resources most efficiently when exploring research priorities to afford knowledge users and population health needs \[[@CR76], [@CR77], [@CR79], [@CR80]\].

Our findings suggest that women are vastly underrepresented in the group of most prolific scientists publishing in high-impact medical journals. This is in direct contrast to recent studies that have identified a gender gap in research publications \[[@CR81]--[@CR84]\]. For example, a previous study \[[@CR84]\] showed that women in first authorship positions increased from 27% in 1994 to 37% in 2014 in leading medical journals (including *Annals of Internal Medicine*, *JAMA Internal Medicine*, *The BMJ*, *JAMA*, *The Lancet* and *The New England Journal of Medicine*), but progress has plateaued or declined since 2009. An urgent need exists to investigate the underlying causes of the potential gender gap to help identify publication practices and strategies to increase women's influence \[[@CR82], [@CR84]\].

Several limitations exist in our study. First, we characterised the knowledge structures generated by a large number of articles published in major medical journals that are included in the WoS database. However, our results are limited to a subset of all clinical-trial-related articles published in 40 leading medical journals. We suspect that these articles represent those that have great implications for clinical practice and that are relevant to clinical practice guidelines and healthcare regulators. Although the publication production analysed has been drawn from an exhaustive analysis of the biomedical literature, possibly, the search missed some relevant articles (and journals). Some reports may be published in journals without being indexed as RCTs, making them difficult to identify. Second, as in many bibliometric analyses, the normalisation of the different names of an author, country and funding sources is fundamentally important to avoiding potential errors. We conducted a careful manual validation of the references and textual data to avoid typographical, transcription and/or indexing errors. However, we recognize this procedure does not assure complete certainty. Third, the affiliation addresses of authors do not necessarily reflect the country where the research was conducted or the research funding source. Fourth, topical analysis that extracts a set of unique keywords, word profiles and co-words may indicate intellectual organization in publication production, albeit with inherent limitations \[[@CR85], [@CR86]\]. Fifth, the use of citation analysis carries some problems \[[@CR87]--[@CR91]\]. A potential length time-effect bias exists, which puts the more recent articles at a disadvantage. In addition, the biomedical literature is rich in barriers and motivations for publication and citation preferences \[[@CR87]\], including self-citation (bias towards one's own work) \[[@CR88]\], language bias (bias towards publishing and citing English articles), omission bias (bias whereby competitors are purposely not cited), and selective reporting and publication bias (bias in which "negative" results are withheld from publication and citation) \[[@CR89]--[@CR92]\]. In addition, citations are also treated as equal regardless of whether research is being cited for its positive contribution to the field or because it is being criticized. Finally, our methods represent only a mapping approach, which could be complemented further by more detailed analyses such as by examining the content (e.g. differences in journal or author characteristics between publicly funded and industry-funded studies, designs/methodology, etc.), the reporting and the reproducible research practices through research of research ("meta-research") studies \[[@CR92]--[@CR98]\].

Conclusion {#Sec15}
==========

The global analysis presented in this study provides evidence of the scientific growth of RCT- related articles published in high-IF medical journals. Over the last 50 years, publication activity in leading medical journals has increased, with Western countries (most notably, the United States) leading but with low- and middle-income countries showing very limited representation. Our analysis contributes to a better conceptualization and understanding of RCT articles and identified the main areas of research, the most influential publication sources chosen for their scientific dissemination and the major scientific leaders. Given the dynamic nature of the field, whether the growth trend remains the same in the coming years and how the characteristics of the field change over time will be interesting to see.
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